[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-neoplasms-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-neoplasms-adult":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100644629","brain-radiotherapy-imaging-for-high-grade-glioma-using-hypoxia-targeting-through-oxygen-enhanced-response-100644629",false,"NCT07670455","Brain Radiotherapy Imaging for High-grade Glioma Using Hypoxia Targeting Through Oxygen-Enhanced Response","BRIGHTER","Inclusion Criteria:\n\n* ≥18yrs.\n* Participants able to communicate with staff and safely comply with the study procedures.\n* Participants to provide informed written consent.\n\nExclusion Criteria:\n\n* Participants with any MRI contraindications including inability to lie flat in MRI scanner, claustrophobia and no foreign bodies, medical devices or other items which are considered an MRI contraindication.\n* Geographically remote patients unable to agree to imaging schedule.\n* Participants with illness or condition which means they cannot understand the requirements of the study.\n* Participants with cardiac or pulmonary disease that are unable to tolerate the flow of oxygen delivered via a mask.\n* Participants who have previously been treated with bleomycin (a chemotherapy used to treat some cancers including Hodgkin lymphoma and germ cell tumours).\n* Participants with contraindications to gadolinium-based contrast agent",true,"ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","High-grade gliomas (HGGs) are the most common type of brain cancer in adults. Life expectancy for patients with HGGs is low. Radiotherapy aims to cure the tumour, but this is hard because HGGs are resistant to treatment. Among the possible causes of resistance may be tumour cells with low-oxygen levels (hypoxia). The investigators know that hypoxia reduces tumour sensitivity to radiotherapy. Using a special imaging technique called oxygen-enhanced MRI (OE-MRI), the investigators can try to identify areas of the tumour with hypoxia. The investigators could then give those areas a higher dose of radiotherapy. This might improve tumour control. This study aims to see if OE-MRI can find low-oxygen areas in HGGs. The study will also assess whether higher radiotherapy doses can be simulated in these regions.\n\nProject summary:\n\n1. Set up the OE-MRI process at Leeds Cancer Centre (LCC). OE-MRI settings will be tested on healthy volunteer participants to ensure the images are as good as possible.\n2. Participant Imaging. Patient participants with HGG will be recruited to take part. OE-MRI will be used to image participants during their treatment and track low-oxygen areas before treatment, halfway through treatment and 3 months after treatment has finished.\n3. Dose Escalation Assessment. Computer programs will be used to design radiotherapy treatments to test if higher radiation doses to the tumour's low-oxygen areas can better control the cancer. This will help understand if this targeted approach has potential benefits. This is modelling and will not alter routine clinical patient participant management.",[27,28,29,30],"High Grade Gliomas","Hypoxia Brain","Glioblastoma (GBM)","Brain Neoplasms, Adult",[32,33,34,35,36,37],"Oxygen-enhanced MRI","OE-MRI","Functional MRI","Hypoxia imaging","Quantitative MRI","Tumour hypoxia","NOT_YET_RECRUITING","2026-06-26",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":21},"2026-09-01",{"date":46,"type":21},"2028-10-31",{"name":48,"class":49},"The Leeds Teaching Hospitals NHS Trust","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":72,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100537080","the-recmap-study-resection-with-or-without-intraoperative-mapping-for-recurrent-glioblastoma-100537080","NCT06273176","The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma","The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2301)","RECMAP","Inclusion Criteria:\n\n1. Age ≥18 years and ≤90 years\n2. Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastoma based on the WHO 2021 classification for glioma\n3. Tumors situated in or near eloquent areas; motor cortex, sensory cortex, subcortical pyramidal tract, speech areas or visual areas as indicated on MRI (Sawaya Grading II and II)19\n4. The tumor is suitable for resection (according to neurosurgeon)\n5. Written informed consent\n\nExclusion Criteria:\n\n1. Tumors of the cerebellum, brainstem, or midline\n2. Multifocal contrast-enhancing lesions\n3. Medical reasons precluding MRI (e.g., pacemaker)\n4. Inability to give written informed consent\n5. Secondary high-grade glioma due to malignant transformation from low-grade glioma\n6. Clinical data unavailable for the newly diagnosed setting","90 Years",{"count":60,"type":21},225,"OBSERVATIONAL","Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma.\n\nThis study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.\n\nThe study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).",[64,65,66,67,68,69,30,70,71],"Glioblastoma, IDH-wildtype","Glioblastoma","Glioblastoma Multiforme of Brain","Astrocytoma, Malignant","Brain Neoplasms","Brain Neoplasms, Adult, Malignant","Recurrent Adult Brain Tumor","Recurrent Glioblastoma",[65,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"Recurrent","Re-resection","Resection","Intraoperative mapping","Awake mapping","Awake craniotomy","Asleep mapping","Motor mapping","Language mapping","Overall survival","Progression-free survival","Neurological morbidity","Quality of life","Functional area","Eloquent","Extent of resection","Residual tumor volume","RECRUITING","2024-02-20",{"date":93,"type":42},"2024-02-22",{"date":95,"type":42},"2023-01-01",{"date":97,"type":21},"2028-01-01",{"name":99,"class":49},"Erasmus Medical Center",8,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":109,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":111,"conditions":112,"keywords":120,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":128,"locationsCount":100},"100525206","the-supramax-study-supramaximal-resection-versus-maximal-resection-for-high-grade-glioma-patients-encram-2201-100525206","NCT06118723","The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)","The SUPRAMAX-study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)","SUPRAMAX","Inclusion Criteria:\n\n1. Age ≥18 years and ≤90 years\n2. Tumor diagnosed as HGG (WHO grade III\u002FIV) on MRI as assessed by the neurosurgeon\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Tumors of the cerebellum, brainstem or midline\n2. Multifocal contrast enhancing lesions\n3. Medical reasons precluding MRI (e.g. pacemaker)\n4. Inability to give written informed consent\n5. Secondary high-grade glioma due to malignant transformation from low-grade glioma\n6. Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin",{"count":110,"type":21},784,"A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). Therefore, this study evaluates the efficacy and safety of SMR with and without mapping techniques in HGG patients in terms of survival, functional, neurological, cognitive, and quality of life outcomes. Furthermore, it evaluates which patients benefit the most from SMR, and how they could be identified preoperatively.\n\nThis study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be operated with supramaximal resection or maximal resection at a 1:3 ratio. Primary endpoints are: 1) overall survival and 2) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months postoperatively. Secondary endpoints are 1) residual CE and NCE tumor volume on postoperative T1-contrast and FLAIR MRI scans 2) progression-free survival; 3) onco-functional outcome, and 4) quality of life at 6 weeks, 3 months, and 6 months postoperatively.\n\nThe study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).",[65,113,64,114,115,116,117,67,68,118,30,119],"High-grade Glioma","Glioblastoma, IDH-mutant","Glioblastoma Multiforme, Adult","Astrocytoma, Grade IV","Astrocytoma, Grade III","Brain Neoplasm, Primary","Brain Neoplasm, Malignant",[65,121,122,123,84,85,82,83],"Supramaximal resection","FLAIRectomy","Non-contrast enhancement",{"date":93,"type":42},{"date":126,"type":42},"2022-01-01",{"date":97,"type":21},{"name":129,"class":49},"Jasper Gerritsen"]